Lexeo Therapeutics (LXEO) Other Operating Expenses (2023 - 2026)

Lexeo Therapeutics' Other Operating Expenses history runs 4 years deep, the most recent figure standing at -$4.7 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 62.52% year-over-year to -$4.7 million; the TTM figure through Mar 2026 stood at -$12.9 million (up 60.41% YoY), while the FY2025 annual figure was -$37.0 million, down 48.06% from the prior year.
• Other Operating Expenses came in at -$4.7 million for Q1 2026 at Lexeo Therapeutics, down from $6.9 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $53.1 million in Q4 2023 to a low of -$12.6 million in Q1 2025.
• A 4-year average of $264300.0 and a median of -$4.5 million in 2024 frame the typical range for Other Operating Expenses.
• On a YoY basis, Other Operating Expenses climbed as much as 158.39% in 2025 and fell as far as 209.04% in 2025.
• Lexeo Therapeutics' Other Operating Expenses stood at $53.1 million in 2023, then plunged by 122.21% to -$11.8 million in 2024, then surged by 158.39% to $6.9 million in 2025, then slumped by 168.35% to -$4.7 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered -$4.7 million, $6.9 million, and -$2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison